3rd International Conference on Rare Diseases and Orphan Drugs
Schedule
Mon, 27 Oct, 2025 at 09:00 am to Tue, 28 Oct, 2025 at 05:00 pm
UTC-08:00Location
Singapore | Singapore, SG
Coalesce Research Group is pleased to announce the 3rd International Conference on Rare Diseases and Orphan Drugs set to take place on October 27–28 2025 in Singapore City Singapore. This two-day conference is designed to serve as a global platform for experts stakeholders and advocates to discuss advancements challenges and opportunities in the rare diseases and orphan drugs sector.
The primary objective of Rare Diseases 2025 is to raise awareness foster collaboration and accelerate progress in addressing the complex needs of individuals affected by rare diseases. The conference will facilitate dialogue and knowledge exchange among diverse stakeholders involved in rare disease research drug development patient care advocacy and policy-making.
The conference may cover a wide range of topics related to rare diseases and orphan drugs including but not limited to:
- Disease epidemiology and genetics
- Advances in diagnosis and screening
- Therapeutic interventions and treatment approaches
- Drug discovery and development strategies
- Regulatory pathways and orphan drug designation
- Patient-centered care and access to treatments
- Health economics and reimbursement issues
- Patient advocacy support and empowerment
Rare Diseases 2025 features keynote presentations plenary sessions panel discussions poster presentations workshops and networking opportunities. It may also include exhibits showcasing the latest advancements in rare disease research diagnostics and therapeutics.
Overall Rare Diseases 2025 plays a crucial role in advancing research innovation and collaboration to improve outcomes and quality of life for individuals living with rare diseases
Who Can Attend?
- Medical Professionals: Doctors Specialists Nurses and Pharmacists
- Researchers and Scientists
- Pharmaceutical Industry Representatives
- Patient Advocates and Organizations
- Regulatory Authorities
- Healthcare Administrators
- Academics and Educators
- Investors and Venture Capitalists
- Government Representatives: Policymakers Lawmakers and Government Officials
- Industry Stakeholders